BERLIN -- Combining enzalutamide (Xtandi) with androgen deprivation therapy (ADT) significantly improved overall survival (OS ...

"It could be cheap, but it still could be poison." -- Stuart Weinerman, MD, of Northwell Health in Great Neck, New York, on ...

BERLIN -- The antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) delivered impressive results in different ...

ORLANDO -- Adalimumab (Humira) was more effective than conventional immunosuppressive drugs at lowering or eliminating the ...

To be a healer is not merely to deliver care, but to create comfort. Yes, science is central, but healing encompasses ...

Shingles vaccination flipped the risks. Vaccinated adults (ages ≥50) who later developed a first-time case of shingles had a ...

More than four out of five deaths (83.9%) were in white patients. That group is more likely to be exposed to risk factors ...

In a randomized trial, 1 day of octreotide infusion combined with endoscopic therapy proved noninferior to 5 days for acute ...

Event-free survival (EFS) improved by 60% and overall survival (OS) by 50% with the antibody-drug conjugate (ADC) enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) versus upfront radical ...

BERLIN -- After multiple failed attempts, an immune checkpoint inhibitor has broken through and landed a significant overall survival (OS) benefit in ovarian cancer, phase III study results showed.

In a study from Korea, adults with type 2 diabetes had a lower risk for autoimmune rheumatic diseases after starting an SGLT2 ...

BERLIN -- Belzutifan (Welireg) induced durable responses in advanced pheochromocytoma or paraganglioma (PPGL) in a single-arm ...